El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 
Carregant...
Miniatura

Tipus de document

Tesi

Versió

Versió publicada

Data de publicació

Llicència de publicació

cc by-nc (c) Chen, Chun-Wei, 2023
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/200979

Pre-clinical development of chimeric virus-like particles based HPV: HIV vaccines by using mammalian cell expression system: limitations and challenges

Títol de la revista

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

Resum

[eng] HPV and HIV-1 are important public health issues in some developing and industrialized countries, but an effective chimeric HPV:HIV preventive vaccine is still unachievable. We aimed to establish an alternative mammalian (293F) cell expression system combining with chromatographic purification methods to reach an appreciable expression level, purity and recovery rate of chimeric HPV:HIV VLPs. In this study, the chimeric HPV:HIV (L1:P18I10 and L1:T20) immunogens were designed and produced by using 293F expression system. The HPV:HIV VLPs were subsequently purified by a 3-step chromatographic method, including cation (CEC), size exclusion (SEC) and heparin affinity (H-AC) chromatography. Then, the in vitro stability, in vitro self assembly and morphology of purified HPV:HIV VLPs were confirmed by non-reducing SDS-PAGE, molecular mass assay, transmission electron microscopy (TEM) respectively. The sequential and conformational P18I10 and T20 peptides presented on chimeric HPV:HIV VLPs were further characterized by HIV-1 anti-V3 and anti-2F5 monoclonal antibodies in vitro by using Western blot and indirect ELISA. Finally, the immunogenicity of HPV:HIV VLPs were assessed in BALB/c mice model. Because the development and manufacturing of an immunogenic HPV:HIV vaccine is still unachievable, this study provided a baseline strategy that may be worthy to support the global efforts to develop novel chimeric VLP-based vaccines for controlling HPV and HIV-1 infections

Matèries (anglès)

Citació

Citació

CHEN, Chun-wei. Pre-clinical development of chimeric virus-like particles based HPV: HIV vaccines by using mammalian cell expression system: limitations and challenges. [consulta: 2 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/200979]

Exportar metadades

JSON - METS

Compartir registre